Contract research and manufacturing company Syngene International has had a fabulous run this year. Its stock price has risen over 40% since January amid robust growth and a positive outlook for the business. Syngene’s market capitalisation has reached INR33,000 crore, surpassing the INR32,600 crore market cap of its parent company Biocon. Since its listing in 2015, the Syngene stock has been rising steadily. Its market cap touched INR20,000
Business News›Prime›Pharma›Syngene gets booster dose of sky-high valuation, but investors cautiously upbeat on stock
Markets
Syngene gets booster dose of sky-high valuation, but investors cautiously upbeat on stock
Synopsis
Despite robust growth prospects acting as a booster dose for the valuation of contract research and manufacturing company Syngene, investors are expected to remain cautious about buying at current levels.
- FONT SIZEAbcSmallAbcMediumAbcLarge
ET
Uh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Get Unlimited Access to The Economic Times
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Minimal AdsComment & Engage with ET Prime community Exclusive invites to Virtual Events with Industry Leaders A trusted team of Journalists & Analysts who can best filter signal from noise Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-
